Scientists in Barcelona discover a potential treatment for cirrhosis Blog Post

Scientists from the Institute for Research in Biomedicine (IRB Barcelona) at PCB and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) reveals a therapeutic target to prevent the development of the many abnormal blood vessels that cause gastrointestinal bleeding—the main complication in cirrhosis. The results of the study have been published in the most recent issue of Cirrhosis is the main risk factor for liver cancer. The same target may be the key to preventing and treating this condition.

 

A new era of research in cancer genomics Blog Post

A study published in the prestigious journal Nature Communications –led by the Centro Nacional de Analisis Genómico (CNAG-CRG), located at the Barcelona Science Park (PCB), and the  German Cancer Research Center (DKFZ)– revealed a high degree of heterogeneity in how cancer genome sequencing is done at different institutions across the globe. The results of this work –carried out within the framework of the International Cancer Genome Consortium (ICGC)– lay the foundation for the coming era of cancer genomics by creating guidelines and providing new tools for achieving higher quality data, for better diagnosis and precision medicine.

d·HEALTH Barcelona now a University of Barcelona Masters degree Blog Post

The Design Health Barcelona (d·HEALTH Barcelona) program, promoted by Biocat to foster innovation and entrepreneurship in the biomedical arena, is now an accredited masters degree offered through the University of Barcelona (UB). d·HEALTH Barcelona, inspired by the Biodesign Innovation Fellowship at Stanford University, is an initiative of Biocat, with support from Sanofi and collaboration from UB, Barcelona Science Park and Danish school KaosPilot, that has become a global benchmark for its disruptive methodology. The third edition begins on 18th January. “Probably the best healthcare innovation accelerator in Europe” according to Health Startup Europe, the first two editions of this program have led to several business projects and 100% of the fellows are still working in the health sector.

 

Biolatam, a benchmark meeting in the series of biotechnology summits worldwide Blog Post

On 16 and 17 November Santiago de Xile hosted the last edition of the largest biotechnology partnering conference in Latin-America, Biolatam 2015.The event, produced by EBD Group and ASEBIO in collaboration with ProChile and Chile Biotech, was attended by over 340 life science dealmakers from pharma, biotech and service companies representing US, Latin American and European entities.organized by the Spanish Association of Biocompanies  (Asebio), EBD Group and Chilean biotechnology companies (Asembio), with the support of ProChile and the Chilebiotech cluster. Leitat, its Biomed Division – which has located its Biomedical Division at PCB– is one of the 30 companies from the Spanish state that took part in this global partnering forum which ranks high in a relevant place in biotechnology summits worlwide.

 

Science Week celebrates its 20th edition with more than 350 activities Blog Post

The 20th Edition of Science Week (SC’15) was inaugurated today, 16 November, at the Institute of Catalan Studies (IEC). The event, coordinated by the Catalan Foundation for Research and Innovation (FCRi), will take place from 13 to 22 November and will host more than 300 different multidisplinary science and technology dissemination activities. SC’15 has the support of nearly 100 institutions and agencies of the Catalan system of research and innovation, most notably the University of Barcelona (UB) and the Catalan Institute for Bioengineering (IBEC) that which will be offering a unique scientific workshop at its premises located at Barcelona Science Park (PCB).

 

New computational approach to predicting adverse drug reactions with higher confidence Blog Post

A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods. This improved ability to foresee the possible adverse effects of drugs may entail saving many lives in the future. The study that is being conducted by researchers from IMIM (Hospital del Mar Medical Research Institute), Pompeu Fabra University (UPF), and the company Chemotargets at PCB, within the framework of the European eTOX project, was chosen for the cover of the journal Chemical Research in Toxicology.

 

The FBG manages a partnership contract between UB, Hospital Clínic and Boehringer to improve the lung cancer treatment Blog Post

In order to advance the fight against lung cancer, the University of Barcelona (UB) and the Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim to look for new ways of nintedanib efficiency, an anti-angiogenic drug for disease treatment. This public-private agreement reflects the commitment of the three organizations involved for quality research on a topic of special emphasis on health such as lung cancer and, in particular squamous carcinoma, which affects about 30% Patients with this type of tumor. The Bosch i Gimpera Foundation (FBG), the Technology Transfer Office of the UB located at PCB, has managed the partnership contract.

 

Spain and France join the European Consortium Elixir for managing and analysing biological data Blog Post

At their meeting today in Hinxton (UK), the Board unanimously accepted Spain and France as full members of Elixir, the largest infrastructure of life science data in Europe. The National Bioinformatics Institute (INB), which acts as the Spanish scientific node, will coordinate the Spanish scientific partner institutions. These comprise top-level institutions such as CNAG-CRG and IRB Barcelona, located at PCB. The National Institute of Health Carlos III (ISCII) will coordinate the Spanish scientific partner institutions.

 

The 20 Severo Ochoa Centers of Excellence organise 100xCIENCIA Forum Blog Post

The 20 Spanish research centers accredited with the Severo Ochoa Excellence distinction– two of which are the Institute for Bioengineering of Catalonia (IBEC) and the Institute for Research in Biomedicine (IRB Barcelona), based at PCB–  met for the first time and for three days, to analyze the current situation of Spanish science and its key actors under the framework of ‘100XCIENCIA Communicating frontier science. The event, which was held from 7 to 9 October in Santa Cruz de la Palma, was closed a clear message: Science has to be conveyed to society for continued growth.